<DOC>
	<DOCNO>NCT00793156</DOCNO>
	<brief_summary>Primary objective multicenter , double-blind , placebo control , randomize withdrawal study determine effectiveness safety orally administer AC-820 dos 2.5 µg 5.0 µg daily patient moderate severe itch associate end-stage renal disease hemodialysis , perform population PK analysis .</brief_summary>
	<brief_title>A Randomized-Withdrawal Phase 3 Study Evaluating Safety Efficacy Oral Nalfurafine HCl ( AC-820 ) Subjects Hemodialysis With Uremic Pruritus ( Renal Itch )</brief_title>
	<detailed_description />
	<mesh_term>Pruritus</mesh_term>
	<criteria>18 yrs old old moderate severe pruritus end stage renal disease 3x weekly hemodialysis pruritus due renal disease abnormal liver function CaP &gt; 80 mg/dl HgB &lt; 8.5 g/dl PTH &gt; pg/mL Within four month spKt/V &lt; 1.05</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>uremic pruritus</keyword>
</DOC>